AKR1C3

Aldo-keto reductase family 1 member C3 · P42330 · AKR1C3 on Sugi Atlas →

217,740 patent compounds predicted against AKR1C3, 131,259 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL28562	0.48	12/20
Flurbiprofen (SCHEMBL2248)	1.00	11/20
Naproxen (SCHEMBL3046)	1.00	11/20
Tarenflurbil (SCHEMBL26131)	1.00	11/20
Naproxen (SCHEMBL42434)	1.00	11/20
Flurbiprofen (SCHEMBL26130)	0.97	11/20
Naproxen (SCHEMBL7362)	0.97	11/20
SCHEMBL59197	0.68	8/20
Cinmetacin (SCHEMBL25138)	0.63	8/20
Cinmetacin (SCHEMBL25139)	0.63	8/20
SCHEMBL6766	0.50	8/20
Indomethacin (SCHEMBL9300)	1.00	7/20
Indomethacin (SCHEMBL42049)	0.98	7/20
Indomethacin (SCHEMBL43583)	0.98	7/20
Indomethacin (SCHEMBL41305)	0.96	7/20
SCHEMBL7002	0.48	7/20
Bermoprofen (SCHEMBL25434)	0.40	7/20
Naproxol (SCHEMBL43203)	0.58	6/20
SCHEMBL60543	0.58	6/20
Xenbucin (SCHEMBL24134)	0.54	6/20

Clinical trials — most relevant to AKR1C3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Role of 5-alpha Reductase in Mediating Testosterone Actions	PHASE4	COMPLETED
ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)	PHASE4	UNKNOWN
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer	PHASE3	COMPLETED
The Effect of Calcium and Vitamin D Supplements on Metabolic and Hormonal Disturbances in Polycystic Ovary Syndrome Patients	PHASE3	COMPLETED
Tolerability of Enteral NAC in Infants	PHASE1	NOT_YET_RECRUITING
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole	nan	WITHDRAWN
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Tissue Predictors of Abiraterone Benefit	nan	COMPLETED
Adrenoleukodystrophy National Registry Study	nan	RECRUITING
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy	nan	RECRUITING
Genetic, Dietary and Environmental Influences on Vitamin D Metabolism	nan	COMPLETED
Gene Polymorphisms Influencing Steroid Synthesis and Action	nan	WITHDRAWN
Environmental and Biological Monitoring Pilot Study for Polycyclic Aromatic Hydrocarbons in Linxian, China	nan	COMPLETED
Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease	nan	COMPLETED
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome	nan	COMPLETED
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases	nan	COMPLETED
Tamoxifen Pharmacogenetics in Asian Breast Cancer Women	nan	UNKNOWN
Individualized Antiretroviral Therapy	nan	COMPLETED
Gene-by-Smoking Interactions and Risk of Atherosclerosis - Ancillary to ARIC	nan	COMPLETED
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6	nan	COMPLETED
Aromatase Inhibitor Clinical Trial	nan	UNKNOWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population	nan	UNKNOWN
Forced Oscillometry in Infants With Bronchopulmonary Dysplasia	nan	RECRUITING
Pharmacogenetic Determinants Of Treatment Response In Children	nan	RECRUITING
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings	nan	COMPLETED
Effects of Vitamin D on Health Promotion During Pregnancy and Its Impact on Prematurity-Related Outcome	nan	UNKNOWN
Genetic Association of Diabetic Retinopathy-1	nan	UNKNOWN
Role of Vitamin C Infusion in Postoperative Mechanically Ventilated Neonates With Sepsis	nan	COMPLETED
Pharmacogenetics of Alcohol: Treatment Implications	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a AKR1C3 binder may also engage these)

Protein	Name	Similarity
Q5R7C9	—	1.000	Q5R7C9 →
AKR1C2	Aldo-keto reductase family 1 member C2	1.000	landscape →
AKR1C1	Aldo-keto reductase family 1 member C1	1.000	landscape →
Q5REQ0	—	1.000	Q5REQ0 →
Q6W8P9	—	1.000	Q6W8P9 →
Q95JH6	—	1.000	Q95JH6 →
Q1XAA8	—	1.000	Q1XAA8 →
Q95JH7	—	1.000	Q95JH7 →
Q95JH5	—	0.999	Q95JH5 →
AKR1C4	Aldo-keto reductase family 1 member C4	0.998	landscape →
P05980	—	0.997	P05980 →
P80508	—	0.995	P80508 →
P52898	—	0.995	P52898 →
Q95JH4	—	0.994	Q95JH4 →
P52897	—	0.991	P52897 →
P70694	—	0.985	P70694 →
D3ZF77	—	0.980	D3ZF77 →
Q91WR5	—	0.965	Q91WR5 →
Q5T2L2	—	0.961	Q5T2L2 →
Q6AYQ2	—	0.955	Q6AYQ2 →
Q8K023	—	0.954	Q8K023 →
P51652	—	0.944	P51652 →
P27118	—	0.942	P27118 →
Q9PTM4	—	0.941	Q9PTM4 →
P27119	—	0.940	P27119 →
B2GV72	—	0.939	B2GV72 →
P47727	—	0.939	P47727 →
P27117	—	0.939	P27117 →
P23457	—	0.938	P23457 →
P97382	—	0.937	P97382 →